Join us November 6th for the International CML Foundation Forum at AORTIC

Join us November 6th for the International CML Foundation Forum at AORTIC

The African Organization for Research and Training in Cancer conference (AORTIC), happening November 5–8, 2019 brings together leading cancer specialists from around the world.

During the conference, attendees are invited to join The Max Foundation and the International and Chronic Myeloid Leukemia Foundation (iCMLf) for an interactive session for African Physicians Treating CML.

When:
Wednesday, November 6 from 5–8 PM at the Radisson Blu Hotel, adjacent to the AORTIC conference center in Maputo, Mozambique.

Discussion Topics:

In this session leading physicians and experts will discuss the following:

  • Monitoring CML in a low-resource setting
  • Responsible management in the era of 5 TIKs
  • Meet the expert: Small group discussions

Get to know the speakers:

This is an opportunity to join in-person to learn from the experts and exchange valuable ideas and transformative practices. Light dinner refreshments will be served.

To reserve your place please email Arlene Harris-Buchan.

Download the invitation here.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation expands collaboration with Pfizer

    The Max Foundation expands collaboration with Pfizer

    The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.

  • The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries

    Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG are joining and committing resources to a unique collaboration Breast cancer is….

  • Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

    Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

    The Max Foundation is thrilled to welcome longtime advisor, Dr. Jerald Radich of the Fred Hutchinson Cancer Research Institute into the Executive Board.  Dr. Radich has been a guiding star in our innovative work for many years helping people face cancer with dignity and hope, especially in the area of improving access to critical diagnostics in low- and middle-income countries.